<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Bursa Malaysia Archives - UMediC Group Berhad</title>
	<atom:link href="https://umedic.com.my/Stagging2025/category/bursa-malaysia/feed/" rel="self" type="application/rss+xml" />
	<link>https://umedic.com.my/Stagging2025/category/bursa-malaysia/</link>
	<description>Bring Excellence in Healthcare</description>
	<lastBuildDate>Tue, 29 Oct 2024 05:35:23 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://umedic.com.my/Stagging2025/wp-content/uploads/2021/10/cropped-umc-32x32.png</url>
	<title>Bursa Malaysia Archives - UMediC Group Berhad</title>
	<link>https://umedic.com.my/Stagging2025/category/bursa-malaysia/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>The Edge &#124; 15 October 2024</title>
		<link>https://umedic.com.my/Stagging2025/the-edge-15-october-2024/</link>
		
		<dc:creator><![CDATA[marketing]]></dc:creator>
		<pubDate>Tue, 29 Oct 2024 05:35:23 +0000</pubDate>
				<category><![CDATA[Bursa Malaysia]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[medical]]></category>
		<category><![CDATA[theedgemarket]]></category>
		<category><![CDATA[umc]]></category>
		<category><![CDATA[UMediC]]></category>
		<category><![CDATA[UMediCGroupBerhad]]></category>
		<guid isPermaLink="false">https://umedic.com.my/Stagging2025/?p=33887</guid>

					<description><![CDATA[<p>&#160; PETALING JAYA: Earnings of healthcare companies in the second half of 2024 (2H24) are likely to come in as strong as posted in 1H24. Affin Hwang Investment Bank Research said healthcare companies under its coverage registered strong second quarter (2Q24) earnings, which were primarily driven by the hospital operators. “We view the recent results [&#8230;]</p>
<p>The post <a href="https://umedic.com.my/Stagging2025/the-edge-15-october-2024/">The Edge | 15 October 2024</a> appeared first on <a href="https://umedic.com.my/Stagging2025">UMediC Group Berhad</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="field field-body">
<div class="dable-content-wrapper">
<div class="newsTextDataWrapInner">&nbsp;</div>
</div>
</div>
<div class="field field-body">
<div class="dable-content-wrapper">
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner">
<div id="div-gpt-ad-inpage" class="inPageAd" data-google-query-id="CMPmvIz8zIUDFfW7SwUdfzYLbA">
<div class="inread_sponsored_ad">
<div class="inread_sponsored">
<div class="inread_sponsored_image_container">
<div class="news-detail_newsTextDataWrap__PkAu5">
<div>
<div class="newsTextDataWrapInner">PETALING JAYA: Earnings of healthcare companies in the second half of 2024 (2H24) are likely to come in as strong as posted in 1H24.</div>
</div>
</div>
</div>
</div>
</div>
</div>
<p>Affin Hwang Investment Bank Research said healthcare companies under its coverage registered strong second quarter (2Q24) earnings, which were primarily driven by the hospital operators.</p>
<p>“We view the recent results positively, as an indication of the sector’s resiliency in earnings delivery and see limited risks in our earnings growth estimates.</p>
<p>“We expect 2H24 to see similar strength (if not more) when compared to 1H24 as there is a lesser seasonality impact from festivities in the latter,” said the research firm.</p>
<p>According to Affin Hwang, the hospital market in Malaysia is likely to grow at an annual growth rate of 5.95% from 2024 to 2029.</p>
<p>It said both&nbsp;<a href="https://www.thestar.com.my/business/marketwatch/stocks/?qcounter=IHH" target="_blank" rel="noopener">IHH Healthcare Bhd</a>&nbsp;and&nbsp;<a href="https://www.thestar.com.my/business/marketwatch/stocks/?qcounter=KPJ" target="_blank" rel="noopener">KPJ Healthcare Bhd</a>&nbsp;are well on track to exceed such expectations.</p>
<p>“We have penciled in strong earnings growth for hospital operators in financial year 2024 (FY24) at 21% to 29%, which we believe is achievable despite the recent foreign exchange (forex) movements.”</p>
<p>&nbsp;</p>
</div>
</div>
</div>
</div>
</div>
</div>
<div class="field field-body">
<div class="dable-content-wrapper">
<p>– The Edge –</p>
</div>
</div>
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner"><a href="https://theedgemalaysia.com/node/708197?fbclid=IwZXh0bgNhZW0CMTEAAR0YiBriHISfgyKZDz9wTWBmywqSkbIanufoEVXWSwdOatEN5x6iDlqvPh4_aem_AfGEnh-wuUVmXSP5P5qmpuRd-SxYgk49ErupN1OonNWT6VtRJ_5a4e9nthudkD89pegARi_n0aKG0y3tGItY3dZ7">theedgemalaysia.com</a></div>
</div>
<p>&nbsp;</p>
</div>
<p>The post <a href="https://umedic.com.my/Stagging2025/the-edge-15-october-2024/">The Edge | 15 October 2024</a> appeared first on <a href="https://umedic.com.my/Stagging2025">UMediC Group Berhad</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>The Edge &#124; 18 April 2024</title>
		<link>https://umedic.com.my/Stagging2025/the-edge-18-april-2024/</link>
		
		<dc:creator><![CDATA[Regine]]></dc:creator>
		<pubDate>Fri, 19 Apr 2024 07:00:16 +0000</pubDate>
				<category><![CDATA[Bursa Malaysia]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[BursaMalaysia]]></category>
		<category><![CDATA[medical]]></category>
		<category><![CDATA[theedgemarket]]></category>
		<category><![CDATA[umc]]></category>
		<category><![CDATA[UMediC]]></category>
		<category><![CDATA[UMediCGroupBerhad]]></category>
		<guid isPermaLink="false">https://umedic.com.my/Stagging2025/?p=33204</guid>

					<description><![CDATA[<p>Bursa approves UMediC’s transfer to Main Market &#160; &#160; KUALA LUMPUR (April 18):&#160;Bursa Malaysia Securities Bhd has approved the transfer of UMediC Group Bhd’s listing status from the ACE Market to the Main Market, under the &#8216;health care&#8217;&#160;sector. &#160; “The transfer will take effect immediately two market days upon the announcement to Bursa Securities on [&#8230;]</p>
<p>The post <a href="https://umedic.com.my/Stagging2025/the-edge-18-april-2024/">The Edge | 18 April 2024</a> appeared first on <a href="https://umedic.com.my/Stagging2025">UMediC Group Berhad</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="field field-body">
<div class="dable-content-wrapper">
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner"><strong>Bursa approves UMediC’s transfer to Main Market</strong></div>
</div>
<div>&nbsp;</div>
</div>
</div>
<div class="field field-body">
<div class="dable-content-wrapper">
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner">&nbsp;</div>
<div id="div-gpt-ad-inpage" class="inPageAd" data-google-query-id="CMPmvIz8zIUDFfW7SwUdfzYLbA">
<div class="inread_sponsored_ad">
<div class="inread_sponsored">
<div class="inread_sponsored_image_container">
<div class="news-detail_newsTextDataWrap__PkAu5">
<div>
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner">
<p>KUALA LUMPUR (April 18):&nbsp;Bursa Malaysia Securities Bhd has approved the transfer of UMediC Group Bhd’s listing status from the ACE Market to the Main Market, under the &#8216;health care&#8217;&nbsp;sector.</p>
<p>&nbsp;</p>
</div>
<div class="newsTextDataWrapInner">
<p>“The transfer will take effect immediately two market days upon the announcement to Bursa Securities on the transfer date via Bursa Link,” said the medical device distributor and manufacturer in a bourse&nbsp;filing on Thursday.</p>
<p>&nbsp;</p>
</div>
<div class="newsTextDataWrapInner">
<p>In a previous filing, UMediC said that it is deemed to have met the requirements for the transfer — namely the profit, financial position and public shareholding spread requirements.&nbsp;</p>
<p>&nbsp;</p>
</div>
<div class="newsTextDataWrapInner">
<p>The group believes its transfer to the Main Market would enhance its credibility and recognition, and reflect its current scale of operations.&nbsp;</p>
<p>&nbsp;</p>
</div>
<div class="newsTextDataWrapInner">
<p>“This, in turn, is expected to improve the liquidity and marketability of UMediC&nbsp;shares,” it said in the past filing.</p>
<p>&nbsp;</p>
</div>
<div class="newsTextDataWrapInner">
<p>The group was listed on the ACE Market on July 26, 2022. It booked a net profit of RM10.36 million and revenue of RM45.43 million for the financial year ended July 31, 2023 (FY2023).</p>
<p>&nbsp;</p>
</div>
<div class="newsTextDataWrapInner">
<p>For the first half ended Jan 31, 2024 (1HFY2024), UMediC’s net profit declined 11.02% to RM4.37 million, from RM4.91 million previously, on higher administrative and marketing expenses. Despite this, revenue expanded 17.5% to RM28 million from RM23.83 million, driven by heightened demand for medical devices and consumables from both public and private hospitals, as well as healthcare service providers.</p>
<p>&nbsp;</p>
</div>
<div class="newsTextDataWrapInner">
<p>Shares in UMediC closed up four sen or 6.3% at 67.5 sen on Thursday, giving the group a market capitalisation of RM252.4 million.</p>
</div>
</div>
</div>
<div class="newsTextDataWrapInner">&nbsp;</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
<div class="field field-body">
<div class="dable-content-wrapper">
<p>&nbsp;</p>
<p>– The Edge –</p>
</div>
</div>
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner"><a href="https://theedgemalaysia.com/node/708500">theedgemalaysia.com</a></div>
</div>
<p>&nbsp;</p>
</div>
<p>The post <a href="https://umedic.com.my/Stagging2025/the-edge-18-april-2024/">The Edge | 18 April 2024</a> appeared first on <a href="https://umedic.com.my/Stagging2025">UMediC Group Berhad</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Capacity expansion, diversification to boost UMediC</title>
		<link>https://umedic.com.my/Stagging2025/capacity-expansion-diversification-to-boost-umedic/</link>
		
		<dc:creator><![CDATA[Regine]]></dc:creator>
		<pubDate>Thu, 18 Apr 2024 07:00:29 +0000</pubDate>
				<category><![CDATA[Bursa Malaysia]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[BursaMalaysia]]></category>
		<category><![CDATA[medical]]></category>
		<category><![CDATA[thestar]]></category>
		<category><![CDATA[umc]]></category>
		<category><![CDATA[UMediC]]></category>
		<category><![CDATA[UMediCGroupBerhad]]></category>
		<guid isPermaLink="false">https://umedic.com.my/Stagging2025/?p=33194</guid>

					<description><![CDATA[<p>&#160; PETALING JAYA: Robust capacity expansion plans and medical equipment tenders are set to drive&#160;UMediC Group Bhd’s (UMC) earnings growth in the near term. Hong Leong Investment Bank Research (HLIB Research) said the medical device maker has relocated its warehouse to a newly built plant, making room for manufacturing-capacity expansion at its existing site, following [&#8230;]</p>
<p>The post <a href="https://umedic.com.my/Stagging2025/capacity-expansion-diversification-to-boost-umedic/">Capacity expansion, diversification to boost UMediC</a> appeared first on <a href="https://umedic.com.my/Stagging2025">UMediC Group Berhad</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="field field-body">
<div class="dable-content-wrapper">
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner">&nbsp;</div>
</div>
</div>
</div>
<p>PETALING JAYA: Robust capacity expansion plans and medical equipment tenders are set to drive&nbsp;<a href="https://www.thestar.com.my/business/marketwatch/stocks/?qcounter=UMC" target="_blank" rel="noopener">UMediC Group Bhd</a><a href="http://charts.thestar.com.my/?s=UMC" target="_blank" rel="noopener"><img decoding="async" class="go-chart" src="https://cdn.thestar.com.my/Themes/img/chart.png"></a>’s (UMC) earnings growth in the near term.</p>
<p>Hong Leong Investment Bank Research (HLIB Research) said the medical device maker has relocated its warehouse to a newly built plant, making room for manufacturing-capacity expansion at its existing site, following the completion of the group’s new facility.</p>
<p>&nbsp;</p>
<div class="field field-body">
<div class="dable-content-wrapper">
<p>The new facility is awaiting regulatory approvals.</p>
<p>“Production capacity is expected to reach 420,000 bottles per month by April 2024 (from 300,000 units per month currently), which is then expected to increase to 600,000 bottles per month by December 2024,” the research house said in a report yesterday.</p>
<p>HLIB Research said the necessary equipment to produce up to 600,000 bottles has been successfully installed at UMC’s production facility.</p>
<p>Currently, UMC is conducting thorough test runs to ensure adherence to quality standards, before a gradual ramping up of production.</p>
<p>“Considering the robust demand for its HydroX prefilled humidifier, we acknowledge the potential for further capacity expansion beyond the completion of the ongoing expansion,” the research firm said.</p>
<p>Apart from that, UMC’s medical equipment tenders for new hospitals and expansion projects continued to remain strong, alongside the emergence of tenders for routine medical equipment replacement.</p>
<p>HLIB Research noted that some of the tenders are taking on a leasing model as opposed to upfront lump-sum payments upon equipment delivery.</p>
<p>A leasing model entails staggered payment for equipment, either with a monthly or quarterly payment.</p>
<p>“This signals the government’s initial venture into the leasing model and if successful, we anticipate a potential increase in similar tenders in the future.</p>
<p>“This transition could prove advantageous for UMC, as it would necessitate the participation of suppliers with solid financial standing due to the lengthened payment period, potentially side-lining smaller competitors,” the research house said.</p>
<p>UMC has also recently diversified into healthcare services with the establishment of the UMC Care Centre.</p>
<p>This is a brand new venture, complementing its core business of medical-equipment distribution.</p>
<p>“The care centre will occupy a four-storey shoplot spanning 7,427 sq ft in Batu Kawan, Penang. It will offer a range of services including aged care, short-term care for post-surgery patients and long-term care for individuals with illnesses,” HLIB Research said.</p>
<p>The research house added that approval for the facility’s floor plan has been obtained from local authorities and renovation work is currently in progress, with completion expected by the end of May. Operations are slated to commence in July 2024.</p>
<p>UMC also recently secured approval to transfer to the Main Market of Bursa Malaysia. The exercise is expected to be completed by the first half of 2024.</p>
<p>“While this transition does not entail any fundamental changes within the company, we regard it as a positive development as it would make UMC more investable, improving participation from institutional investors,” the research house said.</p>
<p>HLIB Research maintained a “buy” call on UMC with a target price of 91 sen. It also advocates investors eyeing long-term growth to accumulate the company’s shares on price weakness.</p>
<p>&nbsp;</p>
<p>– The Star&nbsp; –</p>
</div>
</div>
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner"><a href="https://www.thestar.com.my/business/business-news/2024/04/18/capacity-expansion-diversification-to-boost-umedic?fbclid=IwZXh0bgNhZW0CMTEAAR3luCcghco2N8ayZRiDhF3VRGrz7ESUE-vsONxi5XysvChNtFwn6jXH5sM_aem_AfFZyZiHuHkMATxznrAJBYoKGZZrHHaUAQtasA0NIK5XfeZOkJOslX-kCdj5pCRq3AHer9eeOCEo6AuRCjfgsbr_">www.thestar.com.my</a></div>
</div>
<p>&nbsp;</p>
</div>
<p>The post <a href="https://umedic.com.my/Stagging2025/capacity-expansion-diversification-to-boost-umedic/">Capacity expansion, diversification to boost UMediC</a> appeared first on <a href="https://umedic.com.my/Stagging2025">UMediC Group Berhad</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>UMediC集团 获准转主板</title>
		<link>https://umedic.com.my/Stagging2025/umedic%e9%9b%86%e5%9b%a2-%e8%8e%b7%e5%87%86%e8%bd%ac%e4%b8%bb%e6%9d%bf/</link>
		
		<dc:creator><![CDATA[Regine]]></dc:creator>
		<pubDate>Thu, 04 Apr 2024 07:00:02 +0000</pubDate>
				<category><![CDATA[Bursa Malaysia]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[BursaMalaysia]]></category>
		<category><![CDATA[medical]]></category>
		<category><![CDATA[SINCHEW]]></category>
		<category><![CDATA[umc]]></category>
		<category><![CDATA[UMediC]]></category>
		<category><![CDATA[UMediCGroupBerhad]]></category>
		<guid isPermaLink="false">https://umedic.com.my/Stagging2025/?p=33152</guid>

					<description><![CDATA[<p>&#160; （吉隆坡3日讯）UMediC集团（UMC,0256，创业板医疗保健组）获得证券监督委员会批准转至主板上市。 &#160; 艾芬黄氏投资银行代表UMediC集团董事部宣布，已在周三（3日）收到证监会发出的信函。 &#160; 证监会根据2007年资金市场服务法令，批准了UMediC集团的上市提议以及将产生的股权结构。 &#160; 在2021年10月上市的UMediC集团，是在去年底宣布将申请转至主板。该集团旗下有7家子公司。 &#160; 根据该集团文告，按照现有已发行的3亿7391万股以及每股64.5仙股价计算，其市值约为2亿4117万令吉。 &#160; &#160; – Sin Chew Daily&#160; – www.sinchew.com.my &#160;</p>
<p>The post <a href="https://umedic.com.my/Stagging2025/umedic%e9%9b%86%e5%9b%a2-%e8%8e%b7%e5%87%86%e8%bd%ac%e4%b8%bb%e6%9d%bf/">UMediC集团 获准转主板</a> appeared first on <a href="https://umedic.com.my/Stagging2025">UMediC Group Berhad</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="field field-body">
<div class="dable-content-wrapper">
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner">&nbsp;</div>
</div>
</div>
</div>
</div>
<div class="field field-body">
<div class="dable-content-wrapper">
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner">
<p>（吉隆坡3日讯）UMediC集团（UMC,0256，创业板医疗保健组）获得证券监督委员会批准转至主板上市。</p>
<p>&nbsp;</p>
<p>艾芬黄氏投资银行代表UMediC集团董事部宣布，已在周三（3日）收到证监会发出的信函。</p>
<p>&nbsp;</p>
<p>证监会根据2007年资金市场服务法令，批准了UMediC集团的上市提议以及将产生的股权结构。</p>
<p>&nbsp;</p>
<p>在2021年10月上市的UMediC集团，是在去年底宣布将申请转至主板。该集团旗下有7家子公司。</p>
<p>&nbsp;</p>
<p>根据该集团文告，按照现有已发行的3亿7391万股以及每股64.5仙股价计算，其市值约为2亿4117万令吉。</p>
</div>
</div>
</div>
</div>
</div>
<p>&nbsp;</p>
<p>&nbsp;</p>
<div class="field field-body">
<div class="dable-content-wrapper">
<p>– Sin Chew Daily&nbsp; –</p>
</div>
</div>
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner"><a href="https://www.sinchew.com.my/news/20240403/finance/5508510">www.sinchew.com.my</a></div>
</div>
<p>&nbsp;</p>
</div>
<p>The post <a href="https://umedic.com.my/Stagging2025/umedic%e9%9b%86%e5%9b%a2-%e8%8e%b7%e5%87%86%e8%bd%ac%e4%b8%bb%e6%9d%bf/">UMediC集团 获准转主板</a> appeared first on <a href="https://umedic.com.my/Stagging2025">UMediC Group Berhad</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>UMediC获证监会批准转至主板上市</title>
		<link>https://umedic.com.my/Stagging2025/umedic%e8%8e%b7%e8%af%81%e7%9b%91%e4%bc%9a%e6%89%b9%e5%87%86%e8%bd%ac%e8%87%b3%e4%b8%bb%e6%9d%bf%e4%b8%8a%e5%b8%82/</link>
		
		<dc:creator><![CDATA[Regine]]></dc:creator>
		<pubDate>Thu, 04 Apr 2024 05:00:06 +0000</pubDate>
				<category><![CDATA[Bursa Malaysia]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[BursaMalaysia]]></category>
		<category><![CDATA[medical]]></category>
		<category><![CDATA[theedgemarket]]></category>
		<category><![CDATA[umc]]></category>
		<category><![CDATA[UMediC]]></category>
		<category><![CDATA[UMediCGroupBerhad]]></category>
		<guid isPermaLink="false">https://umedic.com.my/Stagging2025/?p=33148</guid>

					<description><![CDATA[<p>（吉隆坡3日讯）UMediC Group Bhd获得大马证券监督委员会（SC）批准，转至大马交易所主板上市。 &#160; 艾芬黄氏投资银行今日代表UMediC宣布上述消息，指证监会批准了转板上市和由此产生的股权结构。这符合2007年资本市场和服务法令第214（1）条文及上市公司的土著股权要求。 &#160; 该集团于2022年7月26日在创业板上市。 &#160; &#160; 该集团在截至去年7月杪财年（2023财年）净赚1036万令吉，并录得4543万令吉营业额。 &#160; 截至今年1月底首半年，UMediC的净利下跌11.02%至437万令吉，上财年同期为491万令吉，主要是行政和营销开销增加所致。 &#160; 尽管如此，营业额从2383万令吉上涨17.5%，至2800万令吉，得益于政府和私人医院以及医疗服务供应商对医疗设备和消耗品的需求增加。 UMediC由UWC Bhd联合创办人Datuk Ng Chai Eng及Datuk Lau Chee Kheong掌控。 &#160; Ng的私人公司UMediC Capital私人有限公司、他的外甥Eric Lim Taw Seong及商业合作伙伴Lau，共持有UMediC的51.44%股权。他们也各自直接持股5%。 &#160; UMediC今日以62.5仙平盘挂收，市值为2亿3400万令吉。 &#160; &#160; – The Edge – theedgemalaysia.com &#160;</p>
<p>The post <a href="https://umedic.com.my/Stagging2025/umedic%e8%8e%b7%e8%af%81%e7%9b%91%e4%bc%9a%e6%89%b9%e5%87%86%e8%bd%ac%e8%87%b3%e4%b8%bb%e6%9d%bf%e4%b8%8a%e5%b8%82/">UMediC获证监会批准转至主板上市</a> appeared first on <a href="https://umedic.com.my/Stagging2025">UMediC Group Berhad</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="field field-body">
<div class="dable-content-wrapper">
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner">（吉隆坡3日讯）UMediC Group Bhd获得大马证券监督委员会（SC）批准，转至大马交易所主板上市。</div>
<div>&nbsp;</div>
</div>
</div>
</div>
</div>
<div class="field field-body">
<div class="dable-content-wrapper">
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner">
<p>艾芬黄氏投资银行今日代表UMediC宣布上述消息，指证监会批准了转板上市和由此产生的股权结构。这符合2007年资本市场和服务法令第214（1）条文及上市公司的土著股权要求。</p>
<p>&nbsp;</p>
</div>
<div class="newsTextDataWrapInner">
<p>该集团于2022年7月26日在创业板上市。</p>
<p>&nbsp;</p>
</div>
</div>
<div>&nbsp;</div>
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner">
<p>该集团在截至去年7月杪财年（2023财年）净赚1036万令吉，并录得4543万令吉营业额。</p>
<p>&nbsp;</p>
</div>
<div class="newsTextDataWrapInner">
<p>截至今年1月底首半年，UMediC的净利下跌11.02%至437万令吉，上财年同期为491万令吉，主要是行政和营销开销增加所致。</p>
<p>&nbsp;</p>
</div>
<div class="newsTextDataWrapInner">
<p>尽管如此，营业额从2383万令吉上涨17.5%，至2800万令吉，得益于政府和私人医院以及医疗服务供应商对医疗设备和消耗品的需求增加。</p>
</div>
<div class="newsTextDataWrapInner">
<p>UMediC由UWC Bhd联合创办人Datuk Ng Chai Eng及Datuk Lau Chee Kheong掌控。</p>
<p>&nbsp;</p>
</div>
<div class="newsTextDataWrapInner">
<p>Ng的私人公司UMediC Capital私人有限公司、他的外甥Eric Lim Taw Seong及商业合作伙伴Lau，共持有UMediC的51.44%股权。他们也各自直接持股5%。</p>
<p>&nbsp;</p>
</div>
<div class="newsTextDataWrapInner">
<p>UMediC今日以62.5仙平盘挂收，市值为2亿3400万令吉。</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
</div>
</div>
</div>
</div>
</div>
</div>
<div class="field field-body">
<div class="dable-content-wrapper">
<p>– The Edge –</p>
</div>
</div>
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner"><a href="https://theedgemalaysia.com/node/706872">theedgemalaysia.com</a></div>
</div>
<p>&nbsp;</p>
</div>
<p>The post <a href="https://umedic.com.my/Stagging2025/umedic%e8%8e%b7%e8%af%81%e7%9b%91%e4%bc%9a%e6%89%b9%e5%87%86%e8%bd%ac%e8%87%b3%e4%b8%bb%e6%9d%bf%e4%b8%8a%e5%b8%82/">UMediC获证监会批准转至主板上市</a> appeared first on <a href="https://umedic.com.my/Stagging2025">UMediC Group Berhad</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>UMedic Receives SC Nod For Main Market Transfer</title>
		<link>https://umedic.com.my/Stagging2025/umedic-receives-sc-nod-for-main-market-transfer/</link>
		
		<dc:creator><![CDATA[Regine]]></dc:creator>
		<pubDate>Thu, 04 Apr 2024 01:00:14 +0000</pubDate>
				<category><![CDATA[Bursa Malaysia]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[BursaMalaysia]]></category>
		<category><![CDATA[BusinessToday]]></category>
		<category><![CDATA[medical]]></category>
		<category><![CDATA[umc]]></category>
		<category><![CDATA[UMediC]]></category>
		<category><![CDATA[UMediCGroupBerhad]]></category>
		<guid isPermaLink="false">https://umedic.com.my/Stagging2025/?p=33136</guid>

					<description><![CDATA[<p>&#160; UMedic Group Berhad announced that the Securities Commission had approved the group’s proposed transfer tp the main market of Bursa. The group was incorporated in 2021 as a private limited company under the name of UMediC Group Sdn Bhd and was subsequently converted to a public limited company in 2021 and listed on the [&#8230;]</p>
<p>The post <a href="https://umedic.com.my/Stagging2025/umedic-receives-sc-nod-for-main-market-transfer/">UMedic Receives SC Nod For Main Market Transfer</a> appeared first on <a href="https://umedic.com.my/Stagging2025">UMediC Group Berhad</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="field field-body">
<div class="dable-content-wrapper">
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner">&nbsp;</div>
</div>
</div>
</div>
</div>
<div class="field field-body">
<div class="dable-content-wrapper">
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner">
<p>UMedic Group Berhad announced that the Securities Commission had approved the group’s proposed transfer tp the main market of Bursa.</p>
<p>The group was incorporated in 2021 as a private limited company under the name of UMediC Group Sdn Bhd and was subsequently converted to a public limited company in 2021 and listed on the ACE Market of Bursa Securities in 2022.</p>
<p>Based on the Record of Depositors of UMC as at the LPD, approximately 32.92% of the total number of issued Shares were held by 2,731 public shareholders holding not less than 100 Shares each.</p>
<p>UMC market capitalisation is approximately RM241.17 million based on existing 373,910,000 UMC Shares in issue and the closing price of UMC Shares as at the LPD of RM0.645 per Share.</p>
</div>
</div>
</div>
</div>
</div>
<div class="field field-body">
<div class="dable-content-wrapper">
<p>&nbsp;</p>
<p>– Business Today&nbsp; –</p>
</div>
</div>
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner"><a href="https://www.businesstoday.com.my/2024/04/03/umedic-receives-sc-nod-for-main-market-transfer/">www.businesstoday.com.my</a></div>
</div>
<p>&nbsp;</p>
</div>
<p>The post <a href="https://umedic.com.my/Stagging2025/umedic-receives-sc-nod-for-main-market-transfer/">UMedic Receives SC Nod For Main Market Transfer</a> appeared first on <a href="https://umedic.com.my/Stagging2025">UMediC Group Berhad</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Bursa Malaysia’s upward trajectory likely to continue in 1Q2024, says HLIB</title>
		<link>https://umedic.com.my/Stagging2025/bursa-malaysias-upward-trajectory-likely-to-continue-in-1q2024-says-hlib/</link>
		
		<dc:creator><![CDATA[Regine]]></dc:creator>
		<pubDate>Mon, 05 Feb 2024 03:30:37 +0000</pubDate>
				<category><![CDATA[Bursa Malaysia]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[medical]]></category>
		<category><![CDATA[theedgemarket]]></category>
		<category><![CDATA[umc]]></category>
		<category><![CDATA[UMediC]]></category>
		<category><![CDATA[UMediCGroupBerhad]]></category>
		<guid isPermaLink="false">https://umedic.com.my/Stagging2025/?p=32886</guid>

					<description><![CDATA[<p>KUALA LUMPUR (Feb 5): Hong Leong Investment Bank (HLIB) Research said with many negative news already being priced in, it remains constructive on equities. &#160; In a technical tracker on Monday, the research house said this is underpinned by: (i) soft landing narrative in the US amid decelerating inflation, Fed’s expected pivot and stable corporate [&#8230;]</p>
<p>The post <a href="https://umedic.com.my/Stagging2025/bursa-malaysias-upward-trajectory-likely-to-continue-in-1q2024-says-hlib/">Bursa Malaysia’s upward trajectory likely to continue in 1Q2024, says HLIB</a> appeared first on <a href="https://umedic.com.my/Stagging2025">UMediC Group Berhad</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="field field-body">
<div class="dable-content-wrapper">
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner"><a href="https://umedic.com.my/Stagging2025/wp-content/uploads/2024/02/bursa20malaysia20logo20new.webp"><img decoding="async" class="alignnone size-full wp-image-32887" src="https://umedic.com.my/Stagging2025/wp-content/uploads/2024/02/bursa20malaysia20logo20new.webp" alt="" width="1080" height="716" srcset="https://umedic.com.my/Stagging2025/wp-content/uploads/2024/02/bursa20malaysia20logo20new.webp 1080w, https://umedic.com.my/Stagging2025/wp-content/uploads/2024/02/bursa20malaysia20logo20new-980x650.webp 980w, https://umedic.com.my/Stagging2025/wp-content/uploads/2024/02/bursa20malaysia20logo20new-480x318.webp 480w" sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" /></a></div>
</div>
</div>
</div>
</div>
<div class="field field-body">
<div class="dable-content-wrapper">
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner">
<p>KUALA LUMPUR (Feb 5): Hong Leong Investment Bank (HLIB) Research said with many negative news already being priced in, it remains constructive on equities.</p>
<p>&nbsp;</p>
</div>
<div class="newsTextDataWrapInner">
<p>In a technical tracker on Monday, the research house said this is underpinned by: (i) soft landing narrative in the US amid decelerating inflation, Fed’s expected pivot and stable corporate earnings (S&amp;P 500 CY2024/2025: 11%/9%, Factset); (ii) potential stabilisation in China’s economy in anticipation of more concrete measures from the government to rejuvenate its embattled economy and stock markets; (iii) domestic political stability paving the way to pursue greater fiscal and structural reforms, as well as continuous execution of macro blueprints launched in 2023 (ie the National Energy Transition Roadmap (NETR), New Industrial Master Plan 2030, reinvigoration of developments in Johor, subsidy rationalisations, etc); (iv) increased risk appetite by foreigners for the under owned Bursa Malaysia (with foreign shareholding at all-time low of 19.5% in Dec 2023); (v) improved core corporate earnings outlook (CY2023: &#8211; 0.3%, CY2024: +8.2%), anchored primarily by utilities, banks and plantation amid multiple tailwinds from favourable policy, tourism, consumption and currency; and (vi) the “China+One” strategy as global manufacturers trim their dependence on China and reconfigure their supply chains, which in turn will provide trade and investment opportunities for the Asean region (including Malaysia).</p>
</div>
<div class="newsTextDataWrapInner">
<p>&nbsp;</p>
<p>HLIB said the downside risks to its call could arise from (i) new commodity and supply disruptions following renewed geopolitical tensions, especially in the Middle East. Shipping costs between Asia and Europe have increased markedly, as Red Sea attacks reroute cargoes around Africa; (ii) core inflation could prove more persistent and pushback on the timing of Fed’s pivot; (iii) a slower pickup in China’s economy; (iv) heightened US-China tensions; and (iv) renewed sell-off in the ringgit (vs US dollar).</p>
</div>
<div id="div-gpt-ad-inpage" class="inPageAd" data-google-query-id="CIbppeu6k4QDFb_dcwEdhccNrQ">
<div id="google_ads_iframe_/9457649/Inpage_0__container__/CIbppeu6k4QDFb_dcwEdhccNrQ">&nbsp;</div>
</div>
<h3>KLCI target at 1,550</h3>
<div class="newsTextDataWrapInner">
<p>HLIB said current oversold and undemanding KLCI’s CY2024 valuation at 13.6x P/E (slightly below -1SD vs 10Y mean), a decent 4.1% CY2204E DY and all-time low foreign shareholding (end-Dec: 19.5%) would help to cushion any sharp correction.</p>
</div>
<div class="newsTextDataWrapInner">
<p>&nbsp;</p>
<p>“Overall, we take a modest upside bias view to the market with our 2024 KLCI target at 1,550, derived from 15.2x PE (-0.75SD 5Y) tagged to CY24 EPS,” it said.</p>
</div>
<h3>&nbsp;</h3>
<h3>Stock picks</h3>
<div class="newsTextDataWrapInner">
<p>HLIB said its stock picks in February include: (1) SCGM Bhd (promising cable demand from the public and private sectors coupled with margin expansion); (2) MN Holdings Bhd (bright outlook within the data centre industry and power infrastructure anchored by the NETR and TNB’s capex under RP3 &amp; RP4, as well as Corporate Green Power Program (CGPP); (3) MAG Holdings Bhd (well-positioned to capitalise on the sustainable seafood demand in China, as well as the ready-to-eat (RTE) and ready-to-cook (RTC) shrimp products); (4) YTL Power International Bhd (multi-year earnings growth from its data centre foray, a turnaround for Wessex Water and the earnings sustainability of PowerSeraya); (5) AEON Co (M) Bhd (capitalise on the expected turnaround in its Property Management Services and retailing divisions); (6) Focus Point Holdings Bhd (both optical and F&amp;B segments are poised to continue their growth trajectories with the group’s brand equity and popularity of Komugi (a premium Japanese bakery) products); (7) Icon Offshore Bhd (attractive valuations at 8x FY25f P/E vs OGSE’s 12x P/E, supported by a significant upswing in the FY2023-FY2025 EPS CAGR of 109% amid an impending renewal of 11 out of 18 OSVs with the latest daily charter rates); (8) Perdana Petroleum Bhd (a turnaround play and a proxy to the elevated O&amp;G activities benefitting its OSV division); (9) Capital A Bhd (a direct proxy to the buoyant air travel demand recovery and awaiting the impending upliftment of its PN17 status); (10) Teo Seng Capital Bhd (solid near term earnings momentum will sustain into the next few quarters, underpinned by higher production capacity for eggs, recognition of subsidies for eggs, and healthy growth prospects for animal health products.“Over the longer term, we believe egg prices will stay high even post price ceiling and subsidy removal); and (11) UmediC Group Bhd (promising growth trajectory of its manufacturing division post-expansion, as well as its advantageous position to leverage on the government&#8217;s pledge to raise public healthcare expenditure to 5% of GDP).</p>
</div>
</div>
</div>
</div>
</div>
<p>&nbsp;</p>
<div class="field field-body">
<div class="dable-content-wrapper">
<p>– The Edge&nbsp; –</p>
</div>
</div>
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner"><a href="https://theedgemalaysia.com/node/699735">www.theedgemalaysia.com</a></div>
</div>
<p>&nbsp;</p>
</div>
<p>The post <a href="https://umedic.com.my/Stagging2025/bursa-malaysias-upward-trajectory-likely-to-continue-in-1q2024-says-hlib/">Bursa Malaysia’s upward trajectory likely to continue in 1Q2024, says HLIB</a> appeared first on <a href="https://umedic.com.my/Stagging2025">UMediC Group Berhad</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>UMC&#8217;s capacity likely to double by the end of the year</title>
		<link>https://umedic.com.my/Stagging2025/umcs-capacity-likely-to-double-by-the-end-of-the-year/</link>
		
		<dc:creator><![CDATA[marketing]]></dc:creator>
		<pubDate>Fri, 12 Jan 2024 05:45:43 +0000</pubDate>
				<category><![CDATA[Bursa Malaysia]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Ace Market]]></category>
		<category><![CDATA[BursaMalaysia]]></category>
		<category><![CDATA[healthcaremalaysia]]></category>
		<category><![CDATA[successful]]></category>
		<category><![CDATA[thestar]]></category>
		<category><![CDATA[UMediC]]></category>
		<category><![CDATA[UMediCGroupBerhad]]></category>
		<guid isPermaLink="false">https://umedic.com.my/Stagging2025/?p=32704</guid>

					<description><![CDATA[<p>PETALING JAYA: UMediC Group Bhd (UMC) will see its capacity doubling by the end of the year, with its new plant up and running, according to Phillip Capital Research. The newly constructed plant is adjacent to the company’s existing factory and it started operations last December. “This new facility will see capacity doubling by the [&#8230;]</p>
<p>The post <a href="https://umedic.com.my/Stagging2025/umcs-capacity-likely-to-double-by-the-end-of-the-year/">UMC&#8217;s capacity likely to double by the end of the year</a> appeared first on <a href="https://umedic.com.my/Stagging2025">UMediC Group Berhad</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>PETALING JAYA: UMediC Group Bhd (UMC) will see its capacity doubling by the end of the year, with its new plant up and running, according to Phillip Capital Research.</p>
<p>The newly constructed plant is adjacent to the company’s existing factory and it started operations last December.</p>
<p>“This new facility will see capacity doubling by the end of 2024. The expansion will be implemented in phases, with 40% scheduled to start up by the first half of 2024 (1H24) followed by the remaining 60% in 2H24.</p>
<p>“UMC also plans to relocate its existing storage to the new facility with the existing factory focusing on clean room and manufacturing processes,” Phillip Capital said in a note to clients yesterday.</p>
<p>UMC is involved in marketing, distribution and manufacturing of medical devices.</p>
<p>Reaffirming its positive outlook on UMC for 2024, the research firm said UMC’s management is also positive about the demand of two new products being rolled out.</p>
<p>One is the prefilled nebulizer, which started production last December. The second new product is the sterile water inhalation, which is scheduled to be launched in 1Q24.</p>
<div id="story-body" class="story bot-15 relative">
<p>“We expect the demand for the new products to drive the strong earnings growth inFY25.</p>
<p>“In terms of new marketing and distribution channels, UMC is actively exploring new locations in Kuala Lumpur and Johor to showcase its medical devices,” said the research house.</p>
<p>On the company’s 2Q24 results, which is slated to be announced in March, Phillip Capital expects earnings to recover sequentially on the back of higher sales and normalization of its marketing costs.</p>
<p>“Recall that 1Q24 margin and profit were impacted by the higher marketing costs and increased administrative expenses as UMC hired additional workers to cater for the new facility.</p>
<p>“With the absence of the lumpy marketing costs incurred last quarter, we expect the earnings before interest, taxes, depreciation, and amortization margin to show sequential improvement in the upcoming quarter,” said the research house.</p>
<p>It maintained a “buy” rating on the stock with a target price of 87 sen, which is pegged at 25 times price-to-earnings multiple.</p>
<p>&nbsp;</p>
</div>
<div class="modal-wrapper">– The Star –&nbsp;</div>
<div><a href="http://thestar.com.my">http://thestar.com.my</a></div>
<div class="row">
<div class="col-xs-12">
<div id="related-stories-links" class="related-story">&nbsp;</div>
</div>
</div>
<div id="newsletterbox" class="med-rec">&nbsp;</div>
<p>The post <a href="https://umedic.com.my/Stagging2025/umcs-capacity-likely-to-double-by-the-end-of-the-year/">UMC&#8217;s capacity likely to double by the end of the year</a> appeared first on <a href="https://umedic.com.my/Stagging2025">UMediC Group Berhad</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Market players laud new rule accelerating transfer of listing</title>
		<link>https://umedic.com.my/Stagging2025/market-players-laud-new-rule-accelerating-transfer-of-listing/</link>
		
		<dc:creator><![CDATA[Regine]]></dc:creator>
		<pubDate>Wed, 27 Dec 2023 08:42:02 +0000</pubDate>
				<category><![CDATA[Bursa Malaysia]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Ace Market]]></category>
		<category><![CDATA[financial]]></category>
		<category><![CDATA[medical]]></category>
		<category><![CDATA[theedgemarket]]></category>
		<category><![CDATA[umc]]></category>
		<category><![CDATA[UMediC]]></category>
		<category><![CDATA[UMediCGroupBerhad]]></category>
		<guid isPermaLink="false">https://umedic.com.my/Stagging2025/?p=32658</guid>

					<description><![CDATA[<p>&#160; This article first appeared in Capital, The Edge Malaysia Weekly on December 18, 2023 &#8211; December 24, 2023 &#160; SETTING the requirement of RM1 billion in market capitalisation for at least a six-month period and a profit track record is a fair move under the newly unveiled accelerated listing transfer framework for ACE Market-listed [&#8230;]</p>
<p>The post <a href="https://umedic.com.my/Stagging2025/market-players-laud-new-rule-accelerating-transfer-of-listing/">Market players laud new rule accelerating transfer of listing</a> appeared first on <a href="https://umedic.com.my/Stagging2025">UMediC Group Berhad</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="field field-body">
<div class="dable-content-wrapper">
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner">
<div id="attachment_32663" style="width: 1090px" class="wp-caption alignnone"><a href="https://umedic.com.my/Stagging2025/wp-content/uploads/2023/12/TheEdge.webp"><img decoding="async" aria-describedby="caption-attachment-32663" class="wp-image-32663 size-full" src="https://umedic.com.my/Stagging2025/wp-content/uploads/2023/12/TheEdge.webp" alt="" width="1080" height="720" srcset="https://umedic.com.my/Stagging2025/wp-content/uploads/2023/12/TheEdge.webp 1080w, https://umedic.com.my/Stagging2025/wp-content/uploads/2023/12/TheEdge-980x653.webp 980w, https://umedic.com.my/Stagging2025/wp-content/uploads/2023/12/TheEdge-480x320.webp 480w" sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" /></a><p id="caption-attachment-32663" class="wp-caption-text">(Photo by Low Yen Yeing/The Edge)</p></div>
</div>
</div>
</div>
</div>
</div>
</div>
<div class="field field-body">
<div class="dable-content-wrapper">
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner">
<p>&nbsp;</p>
<p>This article first appeared in Capital, The Edge Malaysia Weekly on December 18, 2023 &#8211; December 24, 2023</p>
<p>&nbsp;</p>
</div>
<div class="newsTextDataWrapInner">
<p>SETTING the requirement of RM1 billion in market capitalisation for at least a six-month period and a profit track record is a fair move under the newly unveiled accelerated listing transfer framework for ACE Market-listed players seeking a move to the Main Market of Bursa Malaysia, according to market players. This compares with at least RM500 million in market cap under the existing listing transfer framework.</p>
<p>&nbsp;</p>
</div>
<div class="newsTextDataWrapInner">
<p>Astramina Advisory Sdn Bhd founder and managing director Datin Wong Muh Rong is pleased with the Securities Commission Malaysia’s (SC) move to further relax the rules for listing transfer, especially when the listed companies are of a certain size in terms of market cap and profits.</p>
<p>&nbsp;</p>
</div>
<div class="newsTextDataWrapInner">
<p>“If companies can have a RM1 billion market cap for six months, it means these companies, in the eyes of the capital market, have reached the standard of the Main Market, so they should be automatically invited to transfer to the next level. While not all, but typically, companies that have reached a certain size in terms of their market cap and profits, will attract higher quality shareholders. Thus, these companies pay more attention to governance issues, whether or not the authorities impose it,” she tells The Edge.</p>
</div>
<div class="mt-3 imgw-200 embed-right">
<div style="width: 268px" class="wp-caption alignright"><a class="mobx embedimg-icon" href="https://myassets.theedgemalaysia.com/pics/2023/P39-Muh-Rong-TEM1503_theedgemalaysia.jpg" data-rel="ceolightbox"><img decoding="async" src="https://myassets.theedgemalaysia.com/pics/2023/P39-Muh-Rong-TEM1503_theedgemalaysia.jpg" alt="" width="258" height="316"></a><p class="wp-caption-text">Astramina Advisory’s Muh Rong: If companies can have a RM1 billion market cap for six months, it means these companies, in the eyes of the capital market, have reached the standard of the Main Market, so they should be automatically invited to transfer to the next level (Photo by LinkedIn)</p></div>
<div class="thumb-cap" style="text-align: right;">&nbsp;</div>
</div>
<div class="newsTextDataWrapInner">
<p>Financially, an ACE Market-listed firm is required to achieve an aggregate audited profit after tax (PAT) of at least RM20 million for three to five financial years and a PAT of at least RM6 million in the most recent financial year. At the same time, it has to achieve a sufficient level of working capital for at least 12 months, positive cash flow from operating activities and no accumulated losses, as well as a public shareholding spread requirement of at least 25%.</p>
</div>
<div class="newsTextDataWrapInner">
<p>&nbsp;</p>
<p>The applicant must have been listed on the ACE Market for at least a year and have been operating the same core business for the three most recent financial years.</p>
</div>
<div class="newsTextDataWrapInner">
<p>&nbsp;</p>
<p>According to the revised equity guidelines, in considering a transfer of listing proposal via the market capitalisation test and the accelerated transfer process, the SC will take into account any past record of unusual market activities or other events which may have adversely affected the fair and orderly trading of the listed securities, including any designation or trading restrictions imposed by Bursa Securities up to the past one year prior to submission to the SC.</p>
</div>
<div class="newsTextDataWrapInner">
<p>&nbsp;</p>
<p>Ong Eu Jin, a partner at Rosli Dahlan Saravana Partnership who advises companies on initial public offerings (IPOs), is of the view that the RM1 billion market cap threshold is reasonable given that the share price performance is correlated with the company’s fundamentals. Although the simplified listing transfer framework may speed up the entire process, he cautions that there are qualitative assessments in the application such as the level of corporate governance.</p>
</div>
<div class="newsTextDataWrapInner">
<p>&nbsp;</p>
<p>Genetec Technology Bhd, for example, had to enhance its corporate governance by raising the number of independent directors on its board to more than 50% and women directors to 30% before being granted approval to transfer its listing to the Main Market.</p>
</div>
<div class="newsTextDataWrapInner">
<p>&nbsp;</p>
<p>Companies seeking a transfer of listing from the ACE Market to the Main Market recently include Cnergenz Bhd, UMediC Group Bhd and Hextar Industries Bhd (formerly known as SCH Group Bhd). With their stellar financial performance, Cnergenz and UMediC made their listing transfer application slightly more than a year after being listed on the ACE Market.</p>
</div>
<div class="mt-3 imgw-200 embed-left">
<div style="width: 268px" class="wp-caption alignleft"><a class="mobx embedimg-icon" href="https://myassets.theedgemalaysia.com/pics/2023/P39-Danny-TEM1503_theedgemalaysia.jpg" data-rel="ceolightbox"><img loading="lazy" decoding="async" src="https://myassets.theedgemalaysia.com/pics/2023/P39-Danny-TEM1503_theedgemalaysia.jpg" alt="" width="258" height="316"></a><p class="wp-caption-text">Areca Capital’s Danny: Most investors, especially institutional funds, will look at the liquidity and prospects of each company, rather than whether they are on the ACE or Main Market (Photo by Mohd Izwan Mohd Nazam/The Edge)</p></div>
<div>&nbsp;</div>
<div class="thumb-cap" style="text-align: left;">ACE Market listings have been robust in the past few years. This year alone, 22 companies have been listed on the market, accounting for 73% of the total 30 IPOs on Bursa. Another two ACE Market listings, namely Critical Holdings Bhd and Jati Tinggi Group Bhd, are scheduled for Dec 18 and 20 respectively.</div>
</div>
<div class="newsTextDataWrapInner">
<p>&nbsp;</p>
<p>In a statement last week, the SC said the faster path to the transfer of listing beginning in January 2024 is part of a slew of capital market measures to improve stock market vibrancy and reduce market friction. It is believed that more ACE Market-listed companies will make the effort to improve their corporate values and achieve sustainable growth for shareholders.</p>
</div>
<div class="newsTextDataWrapInner">
<p>&nbsp;</p>
<p>SC chairman Datuk Seri Dr Awang Adek Hussin noted that the transfer to the Main Market was for greater visibility and access to a larger pool of investors, including foreign and institutional investors.</p>
</div>
<div class="newsTextDataWrapInner">
<p>&nbsp;</p>
<p>Areca Capital Sdn Bhd CEO Danny Wong says a company’s financial profile is more important for institutional investors, regardless of where a company is listed. “Most investors, especially institutional funds, will look at the liquidity and prospects of each company, rather than whether they are on the ACE or Main Market. Their earnings performance is more important.”</p>
</div>
<div class="newsTextDataWrapInner">
<p>&nbsp;</p>
<p>Having said that, he expects that the SC’s latest move will help encourage companies to kick-start their journey to the ACE Market.</p>
</div>
<div class="newsTextDataWrapInner">
<p>&nbsp;</p>
<p>“I know some companies don’t want to go to the ACE Market because there is a perception that they’re not as good as companies listed on the Main Market. But now, they may want to list on the ACE Market while waiting to be qualified for the Main Market,” he adds.</p>
</div>
<div class="newsTextDataWrapInner">
<p>&nbsp;</p>
<p>Meanwhile, Astramina Advisory’s Muh Rong is calling for the regulators to consider implementing the accelerated process for transfer of listing from the Leading Entrepreneur Accelerator Platform (LEAP) to the ACE Market. “Companies that have reached a certain size, especially in terms of profits, should be considered for an accelerated transfer to the ACE Market,” she opines.</p>
</div>
<div class="newsTextDataWrapInner">
<p>&nbsp;</p>
<p>Note that the LEAP-to-ACE transfer framework came into effect on April 1. Prior to that, LEAP Market-listed companies had to delist before they could submit an application for a listing on the ACE Market.</p>
</div>
<div class="newsTextDataWrapInner">
<p>&nbsp;</p>
<p>“Good quality companies will definitely be of interest to investors, not just sophisticated investors. By allowing the accelerated market transfer, this will not just encourage more listings, whether on the LEAP Market or ACE Market, but also spur all companies to do better,” she says.</p>
</div>
<div class="newsTextDataWrapInner">
<p>&nbsp;</p>
<p>“This is because they know that their better performance will be rewarded with a higher status — an accelerated market transfer. This is a low cost but extremely effective way to bring more vibrancy to Bursa. This encourages more listings and, at the same time, liquidity also improves because we have better quality companies.”&nbsp;</p>
</div>
</div>
</div>
</div>
<p>&nbsp;</p>
<p>&nbsp;</p>
<div class="field field-body">
<div class="dable-content-wrapper">
<p>– The Edge&nbsp; –</p>
</div>
</div>
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner"><a href="https://theedgemalaysia.com/node/694483?fbclid=IwAR0WkYmgvLCh_hXI43byL0AgbaFSBPXmYVD2-dZHzqtAZVGpGCSghWFKM_s">theedgemalaysia.com</a></div>
</div>
<p>&nbsp;</p>
</div>
<p>The post <a href="https://umedic.com.my/Stagging2025/market-players-laud-new-rule-accelerating-transfer-of-listing/">Market players laud new rule accelerating transfer of listing</a> appeared first on <a href="https://umedic.com.my/Stagging2025">UMediC Group Berhad</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>UMediC’s 1Q PAT Up By 4.7% On Higher Demand For Medical Devices, Consumables</title>
		<link>https://umedic.com.my/Stagging2025/umedics-1q-pat-up-by-4-7-on-higher-demand-for-medical-devices-consumables/</link>
		
		<dc:creator><![CDATA[Regine]]></dc:creator>
		<pubDate>Tue, 05 Dec 2023 06:08:16 +0000</pubDate>
				<category><![CDATA[Bursa Malaysia]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Ace Market]]></category>
		<category><![CDATA[BusinessToday]]></category>
		<category><![CDATA[kualalumpur]]></category>
		<category><![CDATA[medical]]></category>
		<category><![CDATA[stockexchange]]></category>
		<category><![CDATA[umc]]></category>
		<category><![CDATA[UMediC]]></category>
		<category><![CDATA[UMediCGroupBerhad]]></category>
		<guid isPermaLink="false">https://umedic.com.my/Stagging2025/?p=32491</guid>

					<description><![CDATA[<p>UMediC Group Bhd (UMC) recorded a profit before tax (PBT) of RM2.6 million and profit after tax (PAT) of RM2.1 million, an increase of 16.8% and 4.7% respectively, for the first quarter of its financial year ending 31 July 2024 compared to the same quarter last year. For the quarter under review, Malaysia’s leading medical [&#8230;]</p>
<p>The post <a href="https://umedic.com.my/Stagging2025/umedics-1q-pat-up-by-4-7-on-higher-demand-for-medical-devices-consumables/">UMediC’s 1Q PAT Up By 4.7% On Higher Demand For Medical Devices, Consumables</a> appeared first on <a href="https://umedic.com.my/Stagging2025">UMediC Group Berhad</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="field field-body">
<div class="dable-content-wrapper">
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner">
<p>UMediC Group Bhd (UMC) recorded a profit before tax (PBT) of RM2.6 million and profit after tax (PAT) of RM2.1 million, an increase of 16.8% and 4.7% respectively, for the first quarter of its financial year ending 31 July 2024 compared to the same quarter last year.</p>
<p>For the quarter under review, Malaysia’s leading medical device company reported a revenue of RM14.5 million, representing a leap of 28.4% year-on-year (YoY).</p>
<p>“The higher revenue was primarily attributed to both the marketing and distribution as well as manufacturing segments in line with the higher demand for medical devices and consumables both from overseas and local markets.</p>
<p>“In addition, the group also experienced higher sales volume for its manufactured medical consumables, namely HydroX series prefilled humidifiers and AirdroX series inhaler spacers which further alluded to the stronger profitability.</p>
<p>UMC executive director and chief executive officer Lim Taw Seong said entering a new financial year, the group is excited for yet another favourable year ahead.</p>
<p>“This is following the recent budget announcement for 2024 and overseas enquiries on our newly manufactured products, AirdroX and a few more to come next year as we finalise our research and development activities.</p>
<p>“In anticipation of the oncoming demand, we have gradually ramped up our production capabilities which bode well with the nation’s shift from curative to preventive care that could offer new avenues for the group’s next phase of expansion.</p>
<p>“Furthermore, given our proposed transfer to the Main Market of Bursa Malaysia Securities Berhad which is well underway, UMC is strategically well poised to benefit given the ample opportunities ahead,” he said.</p>
</div>
<p>&nbsp;</p>
</div>
</div>
</div>
<div class="field field-body">
<div class="dable-content-wrapper">
<p>– Business Today&nbsp; –</p>
</div>
</div>
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner">
<div class="newsTextDataWrapInner"><a href="https://www.businesstoday.com.my/2023/12/04/umedics-1q-pat-up-by-4-7-on-higher-demand-for-medical-devices-consumables/">www.businesstoday.com.my</a></div>
</div>
<p>&nbsp;</p>
</div>
<p>The post <a href="https://umedic.com.my/Stagging2025/umedics-1q-pat-up-by-4-7-on-higher-demand-for-medical-devices-consumables/">UMediC’s 1Q PAT Up By 4.7% On Higher Demand For Medical Devices, Consumables</a> appeared first on <a href="https://umedic.com.my/Stagging2025">UMediC Group Berhad</a>.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
